Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.

Breckenridge AM, Breckenridge RA, Peck CC.

Br J Clin Pharmacol. 2019 Jul 10. doi: 10.1111/bcp.14026. [Epub ahead of print]

PMID:
31290181
2.

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.

Liberti L, Stolk P, McAuslane JN, Schellens J, Breckenridge AM, Leufkens H.

Oncologist. 2015 Jun;20(6):683-91. doi: 10.1634/theoncologist.2014-0297. Epub 2015 May 6.

3.

Adaptive licensing and facilitated regulatory pathways: A survey of stakeholder perceptions.

Liberti L, Stolk P, McAuslane N, Somauroo A, Breckenridge AM, Leufkens HG.

Clin Pharmacol Ther. 2015 Nov;98(5):477-9. doi: 10.1002/cpt.140. Epub 2015 Jun 30. Review. No abstract available.

PMID:
25877216
4.

Mini-Sentinel and regulatory science--big data rendered fit and functional.

Psaty BM, Breckenridge AM.

N Engl J Med. 2014 Jun 5;370(23):2165-7. doi: 10.1056/NEJMp1401664. No abstract available.

PMID:
24897081
5.

The UK's NHS and pharma: need for more clinical pharmacologists.

Aronson JK, Barnett DB, Breckenridge AM, Ferner RE, Jackson P, Maxwell SR, McInnes GT, Rawlins MD, Ritter JM, Routledge P, Walley TJ, Webb DJ, Williams D, Woods KL.

Lancet. 2009 Apr 11;373(9671):1251-2. doi: 10.1016/S0140-6736(09)60726-1. No abstract available.

PMID:
19362673
6.

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM.

BMJ. 2004 Jul 3;329(7456):15-9.

7.

Reporting of adverse drug reactions by nurses.

Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge AM, Pirmohamed M.

Lancet. 2003 Apr 19;361(9366):1347-8.

PMID:
12711472
8.

The burden of alcohol misuse on an inner-city general hospital.

Pirmohamed M, Brown C, Owens L, Luke C, Gilmore IT, Breckenridge AM, Park BK.

QJM. 2000 May;93(5):291-5.

PMID:
10825405
9.

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.

Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ.

AIDS. 1998 Jul 9;12(10):1163-7.

PMID:
9677165
10.

Clinical pharmacology and malaria.

Breckenridge AM, Winstanley PA.

Ann Trop Med Parasitol. 1997 Oct;91(7):727-33. Review.

PMID:
9625927
11.

Adverse drug reactions.

Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK.

BMJ. 1998 Apr 25;316(7140):1295-8. Review. No abstract available.

12.

Reporting adverse drug reactions in HIV infection.

Arlett PR, Lee EH, Hooker M, Darbyshire JH, Breckenridge AM.

Genitourin Med. 1997 Oct;73(5):335. No abstract available.

13.

Clinical benefit must not be confused with cost benefit.

Rawlins MD, Breckenridge AM.

BMJ. 1998 Jan 24;316(7127):310-1. No abstract available.

14.

Adverse drug reaction of the month--a new series.

Rawlins MD, Breckenridge AM, Wood SM, Waller PC, Coulson R.

Postgrad Med J. 1997 Jul;73(861):385. No abstract available.

15.

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.

Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM, Back DJ.

AIDS. 1997 Mar 15;11(4):F29-33.

PMID:
9084785
16.

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites.

Barry MG, Khoo SH, Veal GJ, Hoggard PG, Gibbons SE, Wilkins EG, Williams O, Breckenridge AM, Back DJ.

AIDS. 1996 Oct;10(12):1361-7.

PMID:
8902065
17.

Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency.

Pirmohamed M, Williams D, Tingle MD, Barry M, Khoo SH, O'Mahony C, Wilkins EG, Breckenridge AM, Park BK.

AIDS. 1996 May;10(5):501-7.

PMID:
8724041
18.

Zidovudine therapy in HIV infection: which patients should be treated and when.

Barry MG, Back DJ, Breckenridge AM.

Br J Clin Pharmacol. 1995 Aug;40(2):107-10. Review. No abstract available.

19.

In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs.

Winstanley PA, Mberu EK, Szwandt IS, Breckenridge AM, Watkins WM.

Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.

20.

Comparison of bioimpedance and Doppler ultrasound cardiac output in CAPD patients.

Ng HW, Walleyl TJ, Tsao Y, Fahal IH, Ahmad R, Breckenridge AM.

Methods Find Exp Clin Pharmacol. 1995 Jan-Feb;17(1):59-65.

PMID:
7623522
21.

Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed.

Waller PC, Wood SM, Breckenridge AM, Rawlins MD.

Br J Clin Pharmacol. 1994 Aug;38(2):93. No abstract available.

22.

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

Barry M, Howe JL, Ormesher S, Back DJ, Breckenridge AM, Bergin C, Mulcahy F, Beeching N, Nye F.

Br J Clin Pharmacol. 1994 May;37(5):421-6.

23.

Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.

Barry M, Howe JL, Back DJ, Swart AM, Breckenridge AM, Weller IV, Beeching N, Nye F.

Br J Clin Pharmacol. 1994 Jan;37(1):7-12.

24.

Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Ng HW, Walley TJ, Tsao Y, Breckenridge AM.

Eur J Clin Pharmacol. 1994;46(4):361-5.

PMID:
7957523
25.

The multiple dose pharmacokinetics of proguanil.

Helsby NA, Edwards G, Breckenridge AM, Ward SA.

Br J Clin Pharmacol. 1993 Jun;35(6):653-6.

26.

Effect of malaria infection and endotoxin-induced fever on phenacetin O-deethylation by rat liver microsomes.

Kokwaro GO, Glazier AP, Ward SA, Breckenridge AM, Edwards G.

Biochem Pharmacol. 1993 Mar 24;45(6):1235-41.

PMID:
8466544
27.

Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis.

Pirmohamed M, Coleman MD, Galvani D, Bucknall RC, Breckenridge AM, Park BK.

Br J Rheumatol. 1993 Mar;32(3):222-6.

PMID:
8095423
28.

The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes.

Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK.

Biochem Pharmacol. 1992 Dec 15;44(12):2307-14.

PMID:
1472096
29.

Reproducibility and comparison of cardiac output measurement by transthoracic bioimpedance and thermodilution methods in critically ill patients.

Ng HW, Coleman N, Walley TJ, Mostafa SM, Breckenridge AM.

Clin Intensive Care. 1993;4(5):217-21.

PMID:
10146700
30.

The binding of the antimalarial arteether to human plasma proteins in-vitro.

Wanwimolruk S, Edwards G, Ward SA, Breckenridge AM.

J Pharm Pharmacol. 1992 Nov;44(11):940-2.

PMID:
1361544
31.

The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients.

Coleman MD, Rhodes LE, Scott AK, Verbov JL, Friedmann PS, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1992 Sep;34(3):244-9.

32.

Review of company postmarketing surveillance studies.

Waller PC, Wood SM, Langman MJ, Breckenridge AM, Rawlins MD.

BMJ. 1992 Jun 6;304(6840):1470-2.

33.

An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro.

Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK.

Biochem Pharmacol. 1992 Apr 15;43(8):1675-82.

PMID:
1575766
34.

Sumatriptan and cerebral perfusion in healthy volunteers.

Scott AK, Grimes S, Ng K, Critchley M, Breckenridge AM, Thomson C, Pilgrim AJ.

Br J Clin Pharmacol. 1992 Apr;33(4):401-4.

35.

Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity.

Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1992 Feb;33(2):183-6.

36.

Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.

Pirmohamed M, Graham A, Roberts P, Smith D, Chadwick D, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1991 Dec;32(6):741-9.

37.

Lack of an interaction between propranolol and sumatriptan.

Scott AK, Walley T, Breckenridge AM, Lacey LF, Fowler PA.

Br J Clin Pharmacol. 1991 Nov;32(5):581-4.

38.
39.

Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.

Pirmohamed M, Coleman MD, Hussain F, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1991 Sep;32(3):303-10.

40.

The influence of alpha 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation.

Mansor SM, Ward SA, Edwards G, Hoaksey PE, Breckenridge AM.

J Pharm Pharmacol. 1991 Sep;43(9):650-4.

PMID:
1685525
41.
42.

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM.

Br J Clin Pharmacol. 1991 Jun;31(6):689-92.

43.

The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.

Coleman MD, Scott AK, Breckenridge AM, Park BK.

Br J Clin Pharmacol. 1990 Nov;30(5):761-7.

44.

The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.

Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM.

Br J Clin Pharmacol. 1990 Oct;30(4):593-8.

45.
46.

Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults.

Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK.

Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):492-5.

PMID:
2091335
47.

The disposition of amodiaquine in Zambians and Nigerians with malaria.

Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G, Orme ML, Breckenridge AM.

Br J Clin Pharmacol. 1990 Jun;29(6):695-701.

48.

The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation.

Mansor SM, Ward SA, Edwards G, Hoaksey PE, Breckenridge AM.

J Pharm Pharmacol. 1990 Jun;42(6):428-32.

PMID:
1979624
49.

25 years of the Committee on Safety of Medicines. An international perspective of the benefits.

Bem JL, Wood SM, West L, Rawlins MD, Breckenridge AM.

Drug Saf. 1990 May-Jun;5(3):161-7. No abstract available.

PMID:
2350440
50.

Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver.

Coleman MD, Hoaksey PE, Breckenridge AM, Park BK.

J Pharm Pharmacol. 1990 May;42(5):302-7.

PMID:
1976775

Supplemental Content

Loading ...
Support Center